| 臺大學術典藏 |
2021-07-03T03:34:46Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:10Z |
Reply
|
Hsu C.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:10Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:33:36Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-07-03T03:33:29Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2021-07 |
A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers
|
Tsai, H;Yang, S;Hsiao, C;Kao, H;Shan, Y;Lin, Y;Yen, C;Du, J;Hsu, C;Wu, I;Chen, L |
| 國家衛生研究院 |
2021-07 |
Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
|
Su, Y;Lin, Y;Hsiao, C;Ou, D;Chen, S;Wu, Y;Lee, W;Lin, J;Hsu, C;Ho, M;Lu, L;Wu, T;Lai, S;Chao, Y;Chou, T;Yen, C;Chen, L;Shan, Y;Cheng, A;Hsu, C |
| 國家衛生研究院 |
2021-07 |
Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load
|
Chen, S;Lai, H;Tsou, H;Shao, Y;Chang, C;Su, T;Liu, T;Chen, L;Cheng, A;Hsu, C |
| 臺大學術典藏 |
2021-06-15T03:12:22Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
Chang Y.-T.; Hsu C.; Jeng Y.-M.; Chang M.-C.; SHU-CHEN WEI; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:18Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; SHU-CHEN WEI; Tien Y.-W.; Hsu C.; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:17Z |
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
|
Hsu C.; SHU-CHEN WEI; Cheng A.-L.; Chen P.-J. |
| 國家衛生研究院 |
2021-06-15 |
Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: Clinical and immunologic perspectives
|
Su, YY;Li, CC;Lin, YJ;Hsu, C |
| 臺大學術典藏 |
2021-06-09T08:12:22Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Wuh-Liang Hwu;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Wu E.-T.; WUH-LIANG HWU; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2021-06-09T08:12:19Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Kuo C.-W.;Wuh-Liang Hwu;Chien Y.-H.;Hsu C.;Hung M.-Z.;Lin I.-L.;Lai F.;Lee N.-C.; Kuo C.-W.; WUH-LIANG HWU; Chien Y.-H.; Hsu C.; Hung M.-Z.; Lin I.-L.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2021-05-26T09:08:26Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; YAO-CHANG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:22Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Hsu C.; Lin M.-T.; Tang J.-L.; Tien H.-F.; Wang C.-H.; YAO-CHANG CHEN |
| 臺大學術典藏 |
2021-05-26T09:08:21Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Liu H.-T.; Hsu C.; Chen C.-L.; Chiang I.-P.; Chen L.-T.; YAO-CHANG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:20Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Hsu C.; Chen C.-L.; Chen L.-T.; Liu H.-T.; YAO-CHANG CHEN; Jan C.-M.; Liu C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:17Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Hsu C.; Wang J.-D.; Hwang J.-S.; Tien H.-F.; Chang S.-M.; Cheng A.-L.; YAO-CHANG CHEN; Tang J.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:10Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; YAO-CHANG CHEN; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2021-05-26T09:08:03Z |
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Ko B.-S.; Chang T.-C.; Hsu C.; YAO-CHANG CHEN; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J.; Liou J.-Y. |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-05-25T06:35:57Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; MING-CHING SHEN; Wang C.-H.; Tien H.-F. |
